Johannes Andel

Steyr, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry.

Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry.

Journal: Breast (Edinburgh, Scotland)

Published: May 24, 2026

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

Journal: EJHaem

Published: February 12, 2024

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Journal: American journal of hematology

Published: August 25, 2023

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.

Journal: Frontiers in oncology

Published: May 30, 2023

Hepatic brucellosis detected by 18F-FDG PET/CT.

Hepatic brucellosis detected by 18F-FDG PET/CT.

Journal: Hellenic journal of nuclear medicine

Published: August 30, 2022

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.

Journal: Breast cancer research : BCR

Published: July 20, 2021

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).

Journal: Therapeutic advances in medical oncology

Published: March 29, 2021

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.

Journal: Wiener klinische Wochenschrift

Published: November 17, 2020

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2020

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.

Journal: Journal of clinical medicine

Published: February 13, 2020

REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer.

REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer.

Journal: Wiener klinische Wochenschrift

Published: February 03, 2020

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

Journal: Therapeutic advances in medical oncology

Published: July 04, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026